Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25896126 | 0.83 | L3MBTL1 (0.41) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL24123680 | 0.81 | P2RX7 (0.31) | — | |
| SCHEMBL24123654 | 0.71 | KDM4C (0.42) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL15007862 | 0.69 | L3MBTL1 (0.56) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL25896124 | 0.67 | L3MBTL1 (0.38) | L3MBTL1KDM4CNPC1RAB9A | |
| SCHEMBL24123655 | 0.66 | MEN1 (0.39) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL20213494 | 0.66 | KDM4C (0.41) | L3MBTL1KDM4CNPC1RAB9AMET | |
| SCHEMBL25896127 | 0.65 | — | — | |
| SCHEMBL24123490 | 0.64 | F2RL3 (0.38) | NPC1RAB9A | |
| SCHEMBL875673 | 0.64 | L3MBTL1 (0.57) | L3MBTL1KDM4CNPC1RAB9AP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-27 | — | — | US | disclosed |
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-27 | — | — | US | disclosed |
| WO-2021255257-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234969-A1 | N-LINKED MACROCYCLIC 7-(PYRAZOL-5-YL)-INDOLE DERIVATIVES AS INHIBIORS OF MCL-1 | MCL1, BAK1, BCL2L1 | L3MBTL1 977/4885KDM4C 2812/4885NPC1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.